Annovis Bio Announces Statistically Significant Phase II/III

Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition measured by ADAS-Cog 11 at three months is...

Related Keywords

Pennsylvania , United States , Hawaii , Malvern , Maria Maccecchini , Annovis Bio , Maccecchinim Buntanetap , Melissa Gaines , Cheng Fang , Alzheimer Research Unit , Hawaii Memory Center Alzheimer Research Unit , Annovis Bio Inc , Securities Exchange , University Hawaii , Company Annual Report On Form , Linkedin , Number Of Responders In Treatment Group , Twitter , Research Development , Mini Mental State Examination , Disease Assessment Scale Cognitive Subscale , Disease Cooperative Study Clinician , Global Impression , Co Primary Endpoint , Meyer Alzheimer , Highly Correlated , Fold Increase , Treatment Group , Memory Disorders , Research Unit , Clinical Professor , Principal Investigator , Hawaii Memory Center , Clinical Operations , Securities Act , Securities Exchange Act , Annual Report , Quarterly Reports , Novel Translational Inhibitor , Multiple Neurotoxic Proteins , Both Alzheimer , Plasma Phosphorylated Tau , Alzheimer Disease , Nat Med ,